Atlas›Domain XII · Complementary, energy & biofield›Guide 165
Guide XII-165

Repurposed-drug protocols (fenbendazole)

Joe Tippens2016United States
A 28 · L 60 · M 1211 interventions in the Trinity explorer
Client cardCompare
[source: …] where a claim comes from[uncertain] not confirmed in a primary source[synthesis] the writer's reconstruction

Version followed: the self-directed "fenben protocol" that spread from the Joe Tippens story (2016 onward) and its later bundling with ivermectin and mebendazole on social media and podcasts, as described by peer-reviewed case reports, regulators, health bodies and fact-checkers. This is a historical account of a harmful practice for recognition and client support. It is not a treatment and nothing here describes how to take any substance.

1. What it was

The practice. "Repurposed-drug protocols" in this guide means lay, self-directed use of veterinary or human antiparasitic drugs (chiefly fenbendazole, a benzimidazole dewormer licensed for livestock and domestic animals; later also ivermectin and mebendazole) as a cancer treatment, outside any prescription, trial or oncology supervision. Fenbendazole is not approved for human use in Canada and neither fenbendazole nor ivermectin is approved there to treat cancer [source: Canadian Press fact check, 2025]. In the UK it is licensed only as an animal medicine [source: Full Fact, 2024].

Origin story. The practice grew from the personal account of Joe Tippens, an American businessman diagnosed with small cell lung cancer in 2016. As reported, he was told in January 2017 that the cancer had spread and that he had about three months to live; he then took a dog parasiticide together with vitamin E and cannabidiol (CBD), and said a scan three months later showed no sign of cancer [source: Korea Times, 2019]. He was at the same time enrolled in a clinical trial of another treatment, which fact-checkers identify as the key confounder in the story [source: Full Fact, 2024; Korea Times, 2019]. He documented the story on his own blog and in a widely shared YouTube video [source: Full Fact, 2024; Krishnan et al., 2026]. The content of his blog is [uncertain: not verified].

Spread.

  • South Korea, 2019: the video circulated through Korean cancer-patient online communities. By September 2019 pharmacies and animal hospitals reported running out of dog dewormers and fielding frequent calls [source: Korea Biomedical Review, 24 Sept 2019; Korea Times, 2019].
  • Japan: a 2021 case report describes an older patient whose family bought a canine dewormer after reading social-media claims that it fought cancer [source: Yamaguchi et al., 2021].
  • Social media generally: the video spawned multiple "fenben protocols" across platforms, and recommendation algorithms steer viewers toward more pro-fenbendazole content with little cautionary information [source: Krishnan et al., 2026]. A survey cited in that report found that roughly 15–20% of cancer patients who use social media for health information had used or seriously considered fenbendazole [source: Krishnan et al., 2026; underlying survey uncertain: not verified].
  • Ivermectin bundle, 2025: on a widely heard podcast in January 2025, the actor Mel Gibson implied that three friends with stage four cancer were cancer-free after ivermectin or fenbendazole; he did not say whether they also had standard treatment. A former Alberta physician whose medical permit is inactive, Viliam Makis, said on X that he had treated one of them with these drugs [source: Canadian Press fact check, 2025].

Stated rationale and how it was sold.

  • Laboratory plausibility: benzimidazoles disrupt microtubules, and cell and mouse studies report anti-tumour effects; promoters present this as proof of a cure [source: Full Fact, 2024; Krishnan et al., 2026]. Animal work is mixed: some studies found no benefit and one reported increased tumour growth [source: Full Fact, 2024; Krishnan et al., 2026].
  • The miracle testimony: a single dramatic recovery story, amplified by video, celebrity and testimonial.
  • Suppression narrative: framed as "a cheap cancer cure they don't want you knowing about" [source: Full Fact, 2024, quoting the X post it checked].
  • Cheapness and availability: sold over the counter as a pet or livestock product, so no prescriber stood between the patient and the drug [source: Korea Biomedical Review, 2019; Yamaguchi et al., 2021].
  • Recommendation by non-medical practitioners: in one US case a holistic healer suggested it as a cancer treatment [source: Krishnan et al., 2026].

Distinguished from legitimate drug repurposing. Repurposing existing drugs for cancer is a real research field. The Repurposing Drugs in Oncology (ReDO) project, by authors linked to the Anticancer Fund and other not-for-profits, reviewed mebendazole as a candidate in 2014, called for human trials, said its proposed combinations were "speculative", and did not advise self-medication; it noted that no mebendazole cancer trial had then been completed and listed early-phase brain-tumour trials under hospital oversight [source: Pantziarka et al., 2014]. A Cedars-Sinai phase I/II trial (NCT05318469) tests ivermectin with an immune checkpoint inhibitor in metastatic triple-negative breast cancer, with eligibility criteria, organ-function checks, exclusions and safety cohorts [source: Cedars-Sinai trial page]. Oncologists interviewed in 2025 noted that most anti-cancer findings for these drugs come from dishes or animals at high concentrations, and that showing benefit needs a trial against standard therapy, which had not been published for ivermectin [source: Canadian Press fact check, 2025]. Korea's National Cancer Center reviewed the feasibility of a fenbendazole trial in 2020 and concluded there was no proven safety or effect even at the animal stage [source: Korea Times, 2020].

2. What was actually done

The following is a composite of a typical course as reported in case reports and news coverage; no single source describes every step [synthesis from the sources cited].

  1. Trigger. Usually a frightening moment in the illness: a poor prognosis, progression, or rising tumour markers. In the Japanese case the patient and family began after becoming worried about a rising tumour marker during immunotherapy [source: Yamaguchi et al., 2021].
  2. Discovery. Through a YouTube video, blog, patient forum, celebrity podcast, social-media post, or a holistic practitioner [source: Korea Biomedical Review, 2019; Krishnan et al., 2026; Canadian Press, 2025].
  3. Selection and "consent". There was no assessment or selection: anyone with any cancer could start. No informed consent process existed; the information people received was testimonial, and the frame ("they don't want you to know") discouraged telling the oncologist [source: Full Fact, 2024; synthesis].
  4. Obtaining the drug. Veterinary products bought from pharmacies, pet shops, animal hospitals or online, often by family members [source: Korea Biomedical Review, 2019; Yamaguchi et al., 2021]. Veterinary antiparasitic products can contain much higher concentrations than human medicines and ingredients never tested in people [source: CDPH ivermectin alert, on veterinary ivermectin].
  5. Self-administration. Taken by mouth at home on schedules copied from online posts, typically stacked with supplements (in the original story, vitamin E and CBD) and, in later variants, with ivermectin or mebendazole [source: Korea Times, 2019; Canadian Press, 2025]. Many people took it alongside ongoing chemotherapy or immunotherapy without telling their team [source: Yamaguchi et al., 2021; Krishnan et al., 2026].
  6. Secrecy. Use came to light only when something went wrong. In the Japanese case, the liver injury was first assumed to be an immunotherapy side effect, and fenbendazole use emerged only when the family was interviewed [source: Yamaguchi et al., 2021].
  7. Judging "progress". By how the person felt, by tumour markers or scans, with any good news credited to the dewormer and any bad news met with persistence [synthesis].
  8. Handling non-response. By escalating: in the US case the patient increased her intake about seven weeks in, and liver symptoms appeared a week later [source: Krishnan et al., 2026]. Adding more agents (ivermectin, mebendazole) is the typical escalation in later variants [source: Canadian Press, 2025; synthesis].
  9. Practitioner-supplied variant. Some people received these drugs through a non-oncology practitioner or a physician outside regulated oncology practice [source: Krishnan et al., 2026; Canadian Press, 2025].

3. How it caused harm

  • Drug-induced liver injury. An 80-year-old woman in Japan with advanced lung adenocarcinoma on pembrolizumab developed markedly raised liver enzymes and bilirubin about a month after starting a canine fenbendazole product, needing urgent admission. Causality was rated "probable". Her liver tests recovered after stopping, and the dewormer produced no tumour shrinkage [source: Yamaguchi et al., 2021]. A 47-year-old woman in the US with metastatic colon cancer on nivolumab/relatlimab developed nausea, fatigue, dark urine, jaundice and severe hepatocellular injury after self-administering fenbendazole on a holistic healer's advice; causality was rated "probable" [source: Krishnan et al., 2026].
  • Interrupted or confused cancer treatment. In both cases the liver injury was first mistaken for immunotherapy hepatitis, and immunotherapy was paused [source: Yamaguchi et al., 2021; Krishnan et al., 2026]. A mistaken label can mean stopping an effective treatment for good, or unnecessary immunosuppression [synthesis]. The 2026 authors stress structured causality assessment for this reason [source: Krishnan et al., 2026].
  • Interaction and frailty risks. Korean authorities warned that taking the drug while weakened by chemotherapy or radiotherapy could cause unexpected side effects, and that long-term high use may damage the blood, nerves or liver [source: Korea Biomedical Review, 2019; Korea Times, 2019]. The Japanese authors could not exclude that pembrolizumab and fenbendazole together increased liver toxicity [source: Yamaguchi et al., 2021].
  • Ivermectin toxicity. Unsupervised ivermectin can cause nausea, vomiting, seizures or death [source: Canadian Press, 2025, quoting a Toronto haematologist]. Veterinary ivermectin poisoning presents with stomach upset, allergic reactions, low blood pressure, and neurological effects from confusion and dizziness to hallucinations, seizures, coma and death [source: CDPH ivermectin alert].
  • Delay or abandonment of effective treatment. The Canadian Cancer Society warned that choosing alternatives over proven treatment can let cancer spread or worsen, and called the promotion dangerous and a source of false hope [source: Canadian Press, 2025]. Experts noted the main danger is that the claims draw patients away from evidence-based care [source: Canadian Press, 2025].
  • False hope and diagnostic overshadowing. Testimonials credit the dewormer for responses that came from concurrent treatment, as in the original story [source: Full Fact, 2024]. Patients and families may then distrust their oncologists [synthesis].
  • Psychological sequelae. Secrecy from the treating team, guilt and regret after harm or progression, family conflict over whether to start or stop, and shame on discovery [synthesis; not documented as such in the sources above].
  • Shortages and community effects. Panic buying emptied pharmacy and veterinary stocks in Korea in 2019 [source: Korea Biomedical Review, 2019].
  • Who was most at risk. People with advanced or progressing cancer and poor prognoses; older patients whose families acquire products for them; people on immunotherapy or chemotherapy (overlapping liver toxicity, confusing presentation); people with existing liver disease [source: Yamaguchi et al., 2021; Krishnan et al., 2026; Full Fact, 2024]; and people already distrustful of medicine or embedded in online communities that reward persistence [synthesis].

4. Recognising it today

Names and phrases you may hear from clients or families [source: Full Fact, 2024; Krishnan et al., 2026; Canadian Press, 2025; Korea Times, 2019; synthesis for grouping]:

  • "Fenben", "the fenben protocol", "the Joe Tippens protocol", "the dog dewormer cure", "dog vermicide".
  • "Repurposed drugs", "off-label protocol", "the dewormer stack", combinations of fenbendazole, ivermectin and mebendazole, sometimes with vitamin E, CBD or other supplements.
  • "A cheap cancer cure they don't want you knowing about"; "Big Pharma can't patent it"; "my oncologist would only dismiss it".
  • "There are hundreds of case reports": online compilations of anecdotal cases circulate, often mixing people who also had standard treatment [uncertain: not verified; synthesis].
  • "A celebrity said his friends with stage four cancer are cured" [source: Canadian Press, 2025].

Behavioural signs in a client with cancer [synthesis]:

  • Buying from pet shops, farm suppliers, veterinary clinics or overseas websites; a family member doing the buying.
  • Reluctance to say what they are "taking for support"; vagueness about supplements; asking you not to mention it to the oncologist.
  • Unexplained new symptoms such as tiredness, nausea, dark urine or yellowing skin or eyes, which the client attributes to chemotherapy or to "detox" (these are the presentations in the published liver-injury case [source: Krishnan et al., 2026]).
  • A sudden pause in immunotherapy "because of the liver" that the client has not linked to anything they took [source: Yamaguchi et al., 2021; Krishnan et al., 2026].
  • Intensifying use or adding agents after bad scan news; considering declining or stopping standard treatment.
  • Heavy time in online groups or video channels about "protocols", with rising distrust of the treating team.

Red flags in a colleague's, practitioner's or service's practice [synthesis, informed by Krishnan et al., 2026; Canadian Press, 2025; APA Ethics Code standards 2.01, 2.04, 3.06]:

  • Recommending or supplying antiparasitic drugs for cancer outside a registered trial or the treating oncologist's care.
  • Advising patients to keep it from their oncologist or to reduce or stop standard treatment.
  • Selling the product, a "protocol", coaching or consultations linked to it, or receiving affiliate income.
  • Presenting laboratory or mouse findings, or single testimonials, as proof of human benefit.
  • A psychotherapist offering opinions on which drugs to take: outside psychological competence regardless of the drug.

How legitimate repurposing research differs [source: Pantziarka et al., 2014; Cedars-Sinai trial page NCT05318469; Canadian Press, 2025; Korea Times, 2020]:

  • It is done as a registered clinical trial with ethics approval, at a recognised centre, with a named investigator.
  • It has eligibility and exclusion criteria (for example, adequate liver and kidney function and exclusion of some interacting medicines) and safety cohorts.
  • It uses pharmaceutical-grade products under medical supervision with monitoring.
  • It is usually tested alongside standard treatment or after it, not instead of it.
  • It makes no promise of cure; researchers state the uncertainty openly.
  • Patients learn about it through their oncologist or a trial registry, not through an anonymous seller.

5. What to do instead and how to help those harmed

Recommended alternatives (for the client to discuss with their medical team, never prescribed by the therapist):

  • Evidence-based oncology care from the treating team; oncologists and health bodies point patients to discussing any new therapy with their doctor [source: Full Fact, 2024, quoting a Cancer Research UK nurse; Canadian Press, 2025].
  • Clinical trials, including trials of repurposed drugs, found through the oncologist or a trial registry; experts named trials as the safer route for interest in these drugs [source: Canadian Press, 2025; Cedars-Sinai trial page].
  • Complementary therapies used alongside standard care and disclosed to the doctor [source: Canadian Press, 2025]; integrative oncology as its societies define it is covered in entry 172.
  • Palliative care and psycho-oncology support, at any stage [synthesis].

Scope. The psychotherapist's role is psychological: conversation, decision support, coordination, emotional care, safeguarding and reporting. The therapist never recommends, supplies, doses or advises starting, stopping or changing any drug, supplement or treatment, and routes every medicine question to the oncologist, prescriber or pharmacist [source: APA Ethics Code 2.01 Boundaries of Competence, 2.04 Bases for Scientific and Professional Judgments; synthesis].

5.1 Asking routinely and without judgement

  • Purpose: to find out early what the client is taking, because use is often hidden until harm occurs. The Japanese authors urge clinicians to ask about supplements and other products taken by mouth [source: Yamaguchi et al., 2021].
  • Steps: (1) Ask everyone with a cancer diagnosis, at intake and after any bad news, about anything they or their family have added. (2) Use a neutral list (vitamins, herbs, CBD, "protocols", products from pet or farm stores, things friends have sent). (3) Record what is disclosed, where it came from and whether the oncologist knows. (4) Thank the client for telling you. [synthesis]
  • Example language (illustrative): "Many people with cancer try things they've read about online, and I ask everyone. Is there anything you or your family have started taking, including things from a pet shop or a website?"
  • Watch for: defensiveness, minimising, a family member answering for the client. It is working when the client discloses and later updates you without prompting.

5.2 Exploring meaning, hopes and the explanatory model

  • Purpose: to understand what the protocol means to the client (control, hope, distrust of medicine, loyalty to a family member, identity in an online community) before any decision discussion [synthesis].
  • Steps: (1) Ask how they came across it and what drew them. (2) Ask what they hope it will do and what it would mean if it didn't. (3) Reflect the fear underneath (often the trigger was bad news, as in the published case [source: Yamaguchi et al., 2021]). (4) Ask what their oncologist has said or what they fear the oncologist would say. (5) Avoid debating evidence at this stage.
  • Example language (illustrative): "It sounds like the rising marker frightened you both, and this felt like something you could actually do. What does taking it give you, day to day?"
  • Watch for: the hope being entirely invested in the protocol; signs of despair underneath; conspiracy framing that sweeps in the therapist. It is working when the client names the feeling ("I can't just wait") as well as the remedy.

5.3 Autonomy-respecting decision support

  • Purpose: to help the client make an informed decision that fits their values, without coercion from you, the family or online groups [source: APA Ethics Code 3.10 Informed Consent, as a principle; synthesis].
  • Steps: (1) Clarify the decision actually on the table (add, continue, stop, or forgo standard treatment). (2) Help the client list questions to take to the oncologist and pharmacist (safety with current treatment, liver monitoring, trial options). (3) Explore values and trade-offs: time, quality of life, family, hope. (4) Share, as information and not as advice, that health bodies say there is no evidence these drugs work in people and that published cases document liver injury [source: Full Fact, 2024; Yamaguchi et al., 2021; Krishnan et al., 2026]. (5) Respect the decision a competent adult makes, while keeping the door open. Published decision aids specific to this situation are [uncertain: not verified].
  • Example language (illustrative): "This is your decision. What I can do is help you get the questions in front of your oncologist so you're deciding with all the information. What would you want to ask?"
  • Watch for: the client feeling judged and going quiet; pressure from relatives; your own urge to persuade. It is working when the client brings the question to the medical team.

5.4 Coordinating with the oncologist and pharmacist

  • Purpose: to make sure the treating team knows, so that liver changes and side effects are interpreted correctly; in both published cases fenbendazole was at first missed and the liver injury attributed to immunotherapy [source: Yamaguchi et al., 2021; Krishnan et al., 2026].
  • Steps: (1) Encourage the client to tell the team themselves; rehearse it. (2) If they agree, obtain written consent to share and limit disclosure to what is needed [source: APA Ethics Code 4.05 Disclosures]. (3) Communicate factually (what, since when, where obtained) without recommendations [source: APA Ethics Code 3.09 Cooperation With Other Professionals; synthesis]. (4) Document.
  • Example language (illustrative): "Would you be willing to tell Dr. [oncologist] at your next visit? If it's easier, we could write it down together, or with your permission I can let the team know."
  • Watch for: refusal driven by fear of being "dropped" by the oncologist; address that fear directly. It is working when the team is informed and the client feels safer, not exposed.

5.5 Recognising and responding to urgent physical risk

  • Purpose: to route possible toxicity to medical care fast.
  • Steps: (1) If a client using these products reports nausea, tiredness, dark urine or yellowing of the skin or eyes, urge same-day contact with the oncology team or urgent care and tell them what was taken [source: symptoms as in Krishnan et al., 2026; synthesis for action]. (2) If ivermectin was taken and the client has confusion, dizziness, hallucinations, seizures, low blood pressure or allergic reactions, advise emergency care or poison control (in the US, 1-800-222-1222) [source: CDPH ivermectin alert]. (3) Never advise on stopping or continuing any medicine; leave that to clinicians. (4) Document.
  • Example language (illustrative): "Yellowing eyes and dark urine need checking today. Please call your oncology team now and tell them about the dewormer as well; they need to know to read your blood tests correctly."
  • Watch for: the client explaining symptoms away as "detox" or "the cancer dying off"; that reframing is itself a reason to act.

5.6 Working with family conflict

  • Purpose: families are often the ones who find the video and buy the product, as in the Japanese case [source: Yamaguchi et al., 2021], and families split between "try everything" and "trust the doctors" [synthesis].
  • Steps: (1) Meet the family with the client's consent; establish that the patient's own wishes lead. (2) Let each member say what they fear and hope for. (3) Reframe the shared goal (more time, comfort, not giving up). (4) Agree that medical questions go to the oncology team, perhaps at a joint appointment. (5) Watch for coercion in either direction. [synthesis]
  • Example language (illustrative): "I'm hearing that you both love her and are frightened, and you've landed on different ways to fight. Can we hear what she wants first?"
  • Watch for: the patient deferring silently to a dominant relative; relatives administering products without the patient's clear agreement (see 5.9). It is working when the patient's voice is heard and the family takes questions to the team together.

5.7 Grief, guilt and regret

  • Purpose: to support clients and bereaved relatives after progression, liver injury, interrupted treatment or death, when they believe the protocol or their choice contributed [synthesis].
  • Steps: (1) Let the regret be spoken without rushing to absolve. (2) Separate hindsight from what was known and felt at the time (fear, hope, love). (3) Address counterfactual rumination and self-blame with established grief and CBT approaches. (4) For relatives who bought the product, address guilt and blame within the family. (5) Watch for complicated grief and depression and treat or refer accordingly. [synthesis]
  • Example language (illustrative): "You chose it because you wanted more time with him. Knowing what you know now hurts, but you didn't have this knowledge then."
  • Watch for: suicidal thinking in intense guilt (assess using standard risk assessment); anger at the oncologists or at the online sources; withdrawal from the community that encouraged it. It is working when self-blame softens into grief.

5.8 Financial harm

  • Purpose: these drugs are often cheap, but costs grow through supplement stacks, paid practitioners, coaching and repeated purchases, and through lost treatment opportunities [synthesis].
  • Steps: (1) Ask what has been spent and on what, including any crowdfunding or family fundraising. (2) Explore pressure to keep buying (group norms, sellers' follow-up). (3) Signpost to financial advice and consumer-protection routes (see 5.10). [synthesis]
  • Example language (illustrative): "Can we look at what all this has cost so far, including the supplements and consultations? Sometimes it adds up in ways that are hard to see."
  • Watch for: shame about money spent; family members financing it under pressure.

5.9 Safeguarding

  • Purpose: to protect people who cannot freely decide: children, adults lacking capacity, and frail older patients whose relatives supply the products [synthesis].
  • Steps: (1) If a child with cancer is being given these products or deprived of medical treatment, follow your local child-protection procedure and consult the child's treating team; involve the child's assent appropriately alongside parental consent. (2) For an adult who may lack capacity or be under coercion, follow adult-safeguarding procedures. (3) Do not name or identify children in any record or report beyond what the procedure requires. (4) Document reasoning and consultation. [synthesis; jurisdiction-specific procedures not verified]
  • Example language (illustrative): "Because your son is a child and is on cancer treatment, I need to make sure his doctors know what he's being given. I'd like to do that with you."
  • Watch for: concealment from the child's oncology team, or withdrawal from treatment.

5.10 Reporting

  • Purpose: suspected adverse reactions and unlawful marketing help regulators act [synthesis].
  • Steps (encourage the client or treating clinician, or report yourself where permitted): (1) Suspected adverse drug reactions: to the national medicines regulator's reporting scheme (e.g. FDA MedWatch in the US, the MHRA Yellow Card scheme in the UK, Health Canada, Korea's MFDS) [uncertain: not verified]. (2) Veterinary products promoted for human cancer: to the veterinary medicines regulator (in the UK, the Veterinary Medicines Directorate licenses these products [source: Full Fact, 2024]) and to advertising or consumer regulators [synthesis]. (3) Clinicians supplying or recommending these drugs outside legitimate practice: to their licensing board. (4) Poisoning: to poison control [source: CDPH ivermectin alert].
  • Example language (illustrative): "What happened to your liver should be reported so regulators can track it. Your doctor can do this, or I can show you how to file it yourself."
  • Watch for: fear of reprisal from online communities; confidentiality limits when reporting a third party. It is working when the client decides whether to report with full information [synthesis].

5.11 The therapist's own conduct

  • Do not sell, supply, endorse or recommend any product or protocol, and avoid conflicts of interest and multiple relationships with sellers [source: APA Ethics Code 3.05 Multiple Relationships, 3.06 Conflict of Interest].
  • Stay within psychological competence; base judgements on established knowledge [source: APA Ethics Code 2.01, 2.04].
  • Notice your own reactions (alarm, contempt, rescue) and seek supervision [synthesis].
  • Example language (illustrative): "I don't recommend, supply or advise on any medicine or protocol. What I can do is help you think it through and take your questions to your oncologist." [synthesis]
  • Watch for: being drawn into endorsing or debating a protocol; any personal or financial tie to sellers or online programmes; your own alarm or rescue impulses shaping sessions. It is working when the client brings medicine questions to the medical team and keeps talking openly with you [synthesis].

Handling problems [synthesis unless cited]

  • Client refuses to tell the oncologist: explore the fear (being scolded, being discharged); rehearse the conversation; offer a joint letter; respect refusal while documenting the risks discussed, unless safeguarding thresholds are met.
  • Client wants you to say whether it works: be clear you cannot advise on medicines; summarise what health bodies say and route to the oncologist and pharmacist [source: Full Fact, 2024; Canadian Press, 2025].
  • Client sends you videos or "case report" compilations: acknowledge the hope in them; do not debate claim by claim; return to the client's decision and questions.
  • Rupture after you raise risk: name it, apologise for any sense of judgement, and reaffirm that the client leads decisions.
  • Client with advanced disease declining further oncology care: support palliative-care referral and advance care planning conversations; separate stopping cancer treatment, which can be a valid choice, from replacing it with a dewormer.
  • Health anxiety or post-treatment fear of recurrence driving "preventive" use: use established psychological approaches for health anxiety and fear of recurrence (see Domain II).
  • Online group pressure: explore the group's role in the client's identity and support; build other sources of connection, such as cancer support organisations.

Sources

Not verified: Joe Tippens' own blog and its current content; the survey on fenbendazole use among cancer patients cited by Krishnan et al. (2026); FDA and EMA statements on fenbendazole cited in that report; a Korean qualitative study of how cancer patients encountered fenbendazole information; national adverse-event reporting scheme details.

← Previous · XII-164Sodium bicarbonate therapy (Simoncini)Next · XII-168 →Naturopathy